Skip to content

Trial Summary

This is a phase II/III, global, multicenter, open-label, multi-cohort study designed to evaluatethe safety and efficacy of targeted therapies or immunotherapy as single agents or incombination in participants with unresectable, advanced or metastatic NS


BO29554 B.FAST

ACTRN/NCT /ethics:


Scientific title:

A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

Sponsor / Cooperative group:


Trial & Patient Characteristics

Cancer TypeLung & mesothelioma
Trial TypeTreatment
PhasePhase II, Phase III
Age Range18 years and older
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced, Metastatic or Widespread
Anticipated Start Date2017-09-22
Anticipated End Date-

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Phone08 8292 2240
Principal InvestigatorDr Nimit Singhal
Recruitment StatusRecruiting